Emergent Biosolutions Inc (NYSE:EBS) Shares Bought by Chatham Capital Group Inc.

Chatham Capital Group Inc. raised its position in Emergent Biosolutions Inc (NYSE:EBS) by 27.5% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 26,812 shares of the biopharmaceutical company’s stock after acquiring an additional 5,789 shares during the period. Chatham Capital Group Inc. owned about 0.05% of Emergent Biosolutions worth $1,355,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in EBS. Norges Bank acquired a new position in shares of Emergent Biosolutions during the 4th quarter worth approximately $49,581,000. Neuberger Berman Group LLC acquired a new stake in Emergent Biosolutions during the third quarter worth approximately $22,064,000. Lord Abbett & CO. LLC acquired a new stake in Emergent Biosolutions during the fourth quarter worth approximately $18,155,000. Atlanta Capital Management Co. L L C acquired a new stake in Emergent Biosolutions during the fourth quarter worth approximately $15,571,000. Finally, BlackRock Inc. grew its stake in Emergent Biosolutions by 3.3% during the fourth quarter. BlackRock Inc. now owns 6,560,237 shares of the biopharmaceutical company’s stock worth $388,890,000 after purchasing an additional 209,332 shares during the period. Hedge funds and other institutional investors own 86.52% of the company’s stock.

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 1,376 shares of Emergent Biosolutions stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $43.39, for a total transaction of $59,704.64. Following the completion of the sale, the director now owns 24,379 shares of the company’s stock, valued at $1,057,804.81. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 14.10% of the company’s stock.

Shares of NYSE EBS traded down $1.47 during mid-day trading on Friday, hitting $43.36. The company had a trading volume of 249,197 shares, compared to its average volume of 498,395. The stock has a market cap of $2.30 billion, a PE ratio of 18.61, a price-to-earnings-growth ratio of 0.73 and a beta of 1.52. Emergent Biosolutions Inc has a 1 year low of $39.64 and a 1 year high of $73.89. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.28 and a current ratio of 2.13.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.26). Emergent Biosolutions had a net margin of 4.88% and a return on equity of 11.73%. The company had revenue of $190.60 million during the quarter, compared to analysts’ expectations of $201.36 million. During the same quarter last year, the firm posted ($0.03) earnings per share. Emergent Biosolutions’s revenue for the quarter was up 61.8% compared to the same quarter last year. On average, sell-side analysts predict that Emergent Biosolutions Inc will post 3.06 EPS for the current year.

Several equities research analysts recently commented on the company. Cowen reaffirmed a “hold” rating and set a $60.00 target price on shares of Emergent Biosolutions in a research note on Friday, May 3rd. Zacks Investment Research lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Monday, April 8th. Wells Fargo & Co set a $68.00 price target on Emergent Biosolutions and gave the stock a “hold” rating in a report on Tuesday, April 2nd. Cantor Fitzgerald reissued a “buy” rating and issued a $75.00 target price on shares of Emergent Biosolutions in a research report on Sunday, April 21st. Finally, Chardan Capital set a $71.00 target price on Emergent Biosolutions and gave the stock a “buy” rating in a research report on Friday, February 22nd. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Emergent Biosolutions has a consensus rating of “Buy” and an average price target of $68.86.

ILLEGAL ACTIVITY NOTICE: “Emergent Biosolutions Inc (NYSE:EBS) Shares Bought by Chatham Capital Group Inc.” was originally published by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://sundanceherald.com/2019/06/14/emergent-biosolutions-inc-ebs-shares-bought-by-chatham-capital-group-inc.html.

Emergent Biosolutions Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Featured Story: What does a market perform rating mean?

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply